{"schema_version":"secwatch.filing_event.v1","accession":"0000849146-23-000205","form_type":"8-K","ticker":"LFVN","cik":"0000849146","company_name":"Lifevantage Corp","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.146746+00:00","generated_at":"2026-06-08T08:15:43.181566+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"LifeVantage Q1 FY24 revenue $51.4M (-0.8% YoY); adj. EBITDA +41%, adj. EPS $0.13","bullets":["Revenue $51.4M, down 0.8% YoY (ex-FX -0.2%). Americas +5.9%, US +6.5%; Asia/Pacific & Europe -16.6% (-14.6% constant currency).","GAAP EPS $0.05 flat YoY; adjusted EPS $0.13 vs $0.06. Adjusted EBITDA $4.0M, up 41.4% from $2.8M.","Total active accounts 137k, down 10.5% YoY (Americas -7.5%, APAC/EU -17.0%). Cash from operations $4.8M vs -$1.3M; no debt.","Dividend $0.035/share declared, payable Dec 15, record Dec 1. FY24 guidance: rev $216M-$226M, adj. EBITDA $16M-$18M, adj. EPS $0.52-$0.62."],"urls":{"canonical":"https://secwatch.observer/filing/0000849146-23-000205","json":"https://secwatch.observer/filing/0000849146-23-000205.json","markdown":"https://secwatch.observer/filing/0000849146-23-000205.md","text":"https://secwatch.observer/filing/0000849146-23-000205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/849146/000084914623000205/0000849146-23-000205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/849146/000084914623000205/lfvn-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:15:43.181566+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0318bdd81a5b1ec85883ec2b482b967f1b575083","claim":"Lifevantage Corp reported the first fiscal quarter ended September 30, 2023 results: revenue $51.4 million, net income $0.6 million, EPS $0.05 per diluted share.","evidence_excerpt":"to activate optimal health processes, today reported financial results for its first fiscal quarter ended September 30, 2023. First Quarter Fiscal 2024 Summary*: • Revenue of $51.4 million, a decrease of 0.8% from the prior year period. Excluding the negative impact of foreign currency fluctuations, first quarter revenue was down approximately 0.2%; • Revenue in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/849146/000084914623000205/0000849146-23-000205-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first fiscal quarter ended September 30, 2023"},{"label":"Revenue","value":"$51.4 million"},{"label":"Net income","value":"$0.6 million"},{"label":"EPS","value":"$0.05 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}